These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36945359)

  • 1. An
    Özbek M; Toy HI; Oktay Y; Karakülah G; Suner A; Pavlopoulou A
    PeerJ; 2023; 11():e15096. PubMed ID: 36945359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
    Wu S; Miao K; Wang L; Ma Y; Wu X
    Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
    Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
    J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data.
    Zhang B; Wu Q; Xu R; Hu X; Sun Y; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Wang Z; Zhou YL
    J Cell Biochem; 2019 Sep; 120(9):15106-15118. PubMed ID: 31020692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and clinical validation of diverse cell-death patterns-associated prognostic features among low-grade gliomas.
    Yang W; Yu H; Lei Q; Pu C; Guo Y; Lin L
    Sci Rep; 2024 May; 14(1):11874. PubMed ID: 38789729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis.
    Chen D; Yao J; Hu B; Kuang L; Xu B; Liu H; Dou C; Wang G; Guo M
    Chin Neurosurg J; 2022 May; 8(1):12. PubMed ID: 35585639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
    Lin WW; Ou GY; Zhao WJ
    J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Bioinformatics Analysis of mRNA Expression Profiles and Identification of a miRNA-mRNA Network Associated with the Pathogenesis of Low-Grade Gliomas.
    Wang M; Cui Y; Cai Y; Jiang Y; Peng Y
    Cancer Manag Res; 2021; 13():5135-5147. PubMed ID: 34234557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of genes related to low-grade glioma progression and prognosis based on integrated transcriptome analysis.
    Jiang Y; He J; Guo Y; Tao H; Pu F; Li Y
    J Cell Biochem; 2020 Jun; 121(5-6):3099-3111. PubMed ID: 31886582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
    Vachher M; Arora K; Burman A; Kumar B
    J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
    Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
    Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma(LGG).
    Liu H; Wang J; Luo T; Zhen Z; Liu L; Zheng Y; Zhang C; Hu X
    Front Endocrinol (Lausanne); 2022; 13():1106120. PubMed ID: 36714574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.